Allele-specific regulation of mutant Huntingtin by Wig1, a downstream target of p53.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Human Molecular Genetics

• Publication date

  2016-05-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/HMG/DDW115PMID 27206983PMCID PMC6086561
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS

  2013cited by this paper
• Role of context in RNA structure: flanking sequences reconfigure CAG motif folding in huntingtin exon 1 transcripts.

  2013cited by this paper
• Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway

  2012cited by this paper
• Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.

  2012cited by this paper
• Reciprocal influence of the p53 and the hypoxic pathways

  2011cited by this paper
• Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.

  2011cited by this paper
• Small Changes, Big Impact

  2011cited by this paper
• Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference

  2011cited by this paper
• Oligonucleotide therapeutic approaches for Huntington disease.

  2011cited by this paper
• Huntington's disease: progress toward effective disease-modifying treatments and a cure.

  2010cited by this paper
• p53 regulation of metabolic pathways.

  2010cited by this paper
• Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat.

  2010cited by this paper
• Molecular mechanisms and potential therapeutical targets in Huntington's disease.

  2010cited by this paper
• Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs

  2009cited by this paper
• Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.

  2009cited by this paper
• CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup.

  2009cited by this paper
• GOSPEL: a neuroprotective protein that binds to GAPDH upon S-nitrosylation.

  2009cited by this paper
• Sustained effects of nonallele‐specific Huntingtin silencing

  2009cited by this paper
• Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice.

  2009cited by this paper
• The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element

  2009cited by this paper
• Specific induction of PAG608 in cranial and spinal motor neurons of L-DOPA-treated parkinsonian rats.

  2008cited by this paper
• Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons.

  2008cited by this paper
• Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits

  2007cited by this paper
• Transcriptional signatures in Huntington's disease.

  2007cited by this paper
• The p53‐induced Wig‐1 protein binds double‐stranded RNAs with structural characteristics of siRNAs and miRNAs

  2006cited by this paper
• Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis.

  2006cited by this paper
• The p53 family in nervous system development and disease

  2006cited by this paper
• p53 tumor suppressor protein regulates the levels of huntingtin gene expression

  2006cited by this paper
• S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding

  2005cited by this paper
• p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease.

  2005cited by this paper
• Normal huntingtin function: an alternative approach to Huntington's disease

  2005cited by this paper
• RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

  2005cited by this paper
• Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease

  2004cited by this paper
• The p53-induced mouse zinc finger protein wig-1 binds double-stranded RNA with high affinity.

  2002cited by this paper
• Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability

  2002cited by this paper
• Identification of functional p53‐binding motifs in the mouse wig‐1 promoter

  2002cited by this paper
• PUMA induces the rapid apoptosis of colorectal cancer cells.

  2001cited by this paper
• Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity

  2001cited by this paper
• Regulation of PTEN transcription by p53.

  2001cited by this paper
• Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53.

  2000cited by this paper
• Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells.

  2000cited by this paper
• The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

  2000cited by this paper
• Expression of cell death-associated phospho-c-Jun and p53-activated gene 608 in hippocampal CA1 neurons following global ischemia.

  1999cited by this paper
• Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin.

  1999cited by this paper
• Wig-1, a new p53-induced gene encoding a zinc finger protein

  1997cited by this paper
• Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.

  1995cited by this paper
• The p53-mdm-2 autoregulatory feedback loop.

  1993cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper

• Progress of p53 Involvement in Central Nervous System Diseases and Targeted Drug Discovery

  2025cites this paper
• ATXN2L primarily interacts with NUFIP2, the absence of ATXN2L results in NUFIP2 depletion, and the ATXN2-polyQ expansion triggers NUFIP2 accumulation

  2025cites this paper
• Pain in Huntington’s disease and its potential mechanisms

  2023cites this paper
• Mutant-Huntingtin Molecular Pathways Elucidate New Targets for Drug Repurposing

  2023cites this paper
• Molecular Pathophysiological Mechanisms in Huntington’s Disease

  2022cites this paper
• Tolfenamic acid inhibits ROS-generating oxidase Nox1-regulated p53 activity in intrastriatal injection of malonic acid rats

  2022cites this paper
• Drug delivery approaches for HuR-targeted therapy for lung cancer.

  2021cites this paper
• Tantalizing role of p53 molecular pathways and its coherent medications in neurodegenerative diseases.

  2021cites this paper
• Transcriptional Dysregulation and Post-translational Modifications in Polyglutamine Diseases: From Pathogenesis to Potential Therapeutic Strategies

  2018cites this paper
• Global neuroprotection of huntingtin in culture and alterations of cortico-striatal connections in Huntington’s disease culture and mouse models

  2017cites this paper
• WIG1 is crucial for AGO2-mediated ACOT7 mRNA silencing via miRNA-dependent and -independent mechanisms

  2017cites this paper